NCT03103555 is a Phase 2 clinical trial of Bortezomib in Adult-onset Immunodeficiency, sponsored by Mahidol University.

Who is sponsoring NCT03103555?

NCT03103555 is sponsored by Mahidol University.

What drugs are being tested in NCT03103555?

Interventions in NCT03103555: Bortezomib, Cyclophosphamide.

What condition does NCT03103555 study?

NCT03103555 studies Adult-onset Immunodeficiency.

Is NCT03103555 still recruiting?

NCT03103555 is currently status unknown. Last updated 6 April 2017.

Last reviewed 2017-04-06 · How we verify

NCT03103555

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Adult-Onset Immunodeficiency With Bortezomib

Status unknown Phase 2 Last updated 6 April 2017

What this trial tests

Phase 2 trial testing Bortezomib in Adult-onset Immunodeficiency in 5 participants. Status unknown.

Timeline

27 February 2017

Primary endpoint
1 November 2018

1 November 2019

Quick facts

Lead sponsor	Mahidol University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	27 February 2017
Primary completion	1 November 2018
Estimated completion	1 November 2019
Sites	1 location across Thailand

Drugs / interventions tested

Bortezomib (bortezomib) — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →

Conditions studied

Adult-onset Immunodeficiency — all drugs for Adult-onset Immunodeficiency →

Sponsor

Mahidol University

Who can join

Adults 21 to 60, any sex, with Adult-onset Immunodeficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is pilot study aimed to investigate the application of proteosome inhibitor, Bortezomib in treatment of patients with neutralizing autoantibody to IFN-γ. The investigators hypothesis is that bortezomib will reduce the antibody level and restore interferon-gamma function, resulting in clinical improvement and should be well-tolerated and safe for use in patients with autoantibody to IFN-γ.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy of Bortezomib for Treating Anti-Interferon-Gamma Autoantibody-Associated Adult-Onset Immunodeficiency Syndrome.
Angkasekwinai N, Suputtamongkol Y, Tantibhedhyangkul W, Onlamoon N, et al · · 2024 · cited 10× · PMID 37947190 · DOI 10.1093/cid/ciad676

Verify or expand the search:

Other trials of Bortezomib

Trials testing the same drug.

NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT07428369 — A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · Phase 2, PHASE3 · not yet recruiting
NCT07224672 — A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, an · Phase 2 · not yet recruiting
NCT07391657 — A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regi · Phase 3 · recruiting

Other Mahidol University trials

Trials by the same sponsor.

NCT07568496 — Greater Occipital Nerve Block for Migraine With Medication Overuse Headache · NA · not yet recruiting
NCT07407400 — Lemborexant for Sleep and Delirium Prevention in Elderly ICU Patients · Phase 4 · not yet recruiting
NCT07378501 — Thai Version of the Pediatric Quality of Recovery Score (PedSQoR): Translation and Psychometric Validation Study · not yet recruiting
NCT07438301 — Septic Shock Hemodynamic Respond to Volume Resuscitation Versus Vasopressor Administration · not yet recruiting
NCT07390006 — Enabling Patient-Reported Outcomes Through Innovative Care - ACS (EPIC-ACS) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03103555 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mahidol University
Last refreshed: 6 April 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03103555.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing